9/13/2021 7:04:40 AM
Alnylam Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy
9/7/2021 7:08:33 AM
Alnylam Presents Addl 9-Month Data From HELIOS-A Phase 3 Study Of Vutrisiran At EU-ATTR Amyloidosis Meeting
8/9/2021 7:04:14 AM
Alnylam Completes Enrollment In HELIOS-B Phase 3 Study Of Vutrisiran
8/3/2021 8:07:22 AM
Alnylam Pharmaceuticals Inc. (ALNY) Has Raised Its FY21 Revenue Estimate To $640 - $665 Mln From $610 - $660 Mln
8/3/2021 8:06:02 AM
Alnylam Pharma Q2 Non-GAAP Net Loss/shr Narrows To $1.30 From $1.67 Prior Year
7/29/2021 7:18:02 AM
Alnylam Reports Positive Results From Phase 3 Study Of Lumasiran In Patients With Advanced Primary Hyperoxaluria Type 1
6/30/2021 7:06:08 AM
Alnylam Pharma Initiates KARDIA-1 Phase 2 Study Of Zilebesiran In Patients With Mild-to-Moderate Hypertension
6/7/2021 7:34:08 AM
Alnylam Announces Positive Results From Phase 3b Study Conducted To Evaluate Safety, Efficacy And PK Of Patisiran
6/1/2021 7:06:10 AM
Alnylam Pharma Completes Enrollment In APOLLO-B Phase 3 Study Of Patisiran In ATTR Patients With Cardiomyopathy
5/11/2021 7:04:48 AM
Alnylam Pharma Begins Clinical Study Of Biannual Dosing Regimen Of Vutrisiran For Transthyretin-mediated Amyloidosis
5/3/2021 7:06:38 AM
Alnylam Pharma Announces Positive Early Results From ILLUMINATE-A Phase 3 Study Of OXLUMO